Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Robert Mashal, an oncology-trained director at Nuvation Bio, purchased 25,000 shares at $4.73 per share on June 9, 2026, bringing his total indirect holdings to 225,000 shares. The purchase comes as Nuvation's first FDA-approved cancer drug, Ibtrozi, continues gaining traction with over 200 new patients per quarter since its July 2025 launch. The stock has surged 96% over the past year, and Wall Street projects revenue will nearly triple to $203 million in 2026.

06/17/2026, 12:01 PM • The Motley Fool

Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 Class A shares for approximately $904,000 on April 6, 2026, reducing his direct holdings by 79%. However, he retains 53,000 shares and 700,000 stock options, suggesting the sale is a routine profit-taking exercise rather than a loss of confidence in the company. Nuvation Bio, a clinical-stage oncology biotech with promising pipeline candidates, reported a net loss of $204.6 million but this is typical for R&D-heavy biotech firms.

04/13/2026, 12:04 AM • The Motley Fool

NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Nuvation Bio Inc. for potential securities law violations following the company's Q4 2025 earnings report. The company revealed that 75% of treatment discontinuations for its IBTROZI oncology therapy occurred in later-line patient populations, contributing to a gap between patient starts and revenue growth. The stock fell 25.3% following this disclosure, prompting the investigation into whether the company issued false or misleading statements.

03/21/2026, 5:15 PM • Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PayPal Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – PYPL

Pomerantz Law Firm has filed class action lawsuits against PayPal Holdings and Snowflake Inc., with deadlines for investors to join. PayPal announced disappointing Q4 2025 earnings, CEO departure, and withdrawn 2027 guidance due to macroeconomic factors and operational issues. The firm is also investigating claims on behalf of Nuvation Bio investors.

03/10/2026, 3:52 PM • GlobeNewswire

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.

02/17/2026, 11:17 AM • Benzinga

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Gary Hattersley, chief scientific officer at Nuvation Bio, exercised and sold 100,000 shares under a pre-planned trading strategy, reducing his direct stock ownership to zero while retaining 298,935 stock options.

11/03/2025, 6:10 AM • The Motley Fool